Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
SYN's Cash-to-Debt is ranked higher than
95% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. SYN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SYN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
93% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -13.36
Beneish M-Score: -14.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -983.72
SYN's ROE % is ranked lower than
98% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. SYN: -983.72 )
Ranked among companies with meaningful ROE % only.
SYN' s ROE % Range Over the Past 10 Years
Min: -983.72  Med: -156.43 Max: -48.04
Current: -983.72
-983.72
-48.04
ROA % -110.69
SYN's ROA % is ranked lower than
87% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. SYN: -110.69 )
Ranked among companies with meaningful ROA % only.
SYN' s ROA % Range Over the Past 10 Years
Min: -174.99  Med: -92.6 Max: -41.8
Current: -110.69
-174.99
-41.8
ROC (Joel Greenblatt) % -4683.57
SYN's ROC (Joel Greenblatt) % is ranked lower than
80% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. SYN: -4683.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SYN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14661.9  Med: -915.08 Max: -112.64
Current: -4683.57
-14661.9
-112.64
3-Year EBITDA Growth Rate 15.50
SYN's 3-Year EBITDA Growth Rate is ranked higher than
66% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. SYN: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SYN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 101.3
Current: 15.5
0
101.3
3-Year EPS without NRI Growth Rate 2.40
SYN's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. SYN: 2.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SYN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 65.1
Current: 2.4
0
65.1
GuruFocus has detected 2 Warning Signs with Synthetic Biologics Inc SYN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SYN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SYN Guru Trades in Q3 2016

Ken Fisher 50,000 sh (+100.00%)
» More
Q4 2016

SYN Guru Trades in Q4 2016

Ken Fisher 133,967 sh (+167.93%)
» More
Q1 2017

SYN Guru Trades in Q1 2017

Jim Simons 22,900 sh (New)
Ken Fisher 133,967 sh (unchged)
» More
Q2 2017

SYN Guru Trades in Q2 2017

Ken Fisher 133,967 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2016-12-31 Add 167.93%$0.76 - $1.77 $ 0.92-21%133,967
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OSL:BGBIO, XPAR:ADOC, NAS:PRQR, ROCO:4193, OTCPK:EGRN, OTCPK:ARTH, XKRX:217730, NAS:BLRX, XTER:VSC, XTER:MGN, ASX:PNV, ROCO:6547, AMEX:MTNB, ASX:NEU, TPE:1734, XCNQ:PBT.U, XTAE:CBI, TSE:2370, XKRX:222110, TSX:IMV » details
Traded in other countries:SFYB.Germany,
Headquarter Location:USA
Synthetic Biologics Inc is a late-stage biotechnology company focused on developing gut microbiome therapeutics. It is also developing monoclonal antibody therapies for the treatment of pertussis.

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Ratios

vs
industry
vs
history
PB Ratio 24.24
SYN's PB Ratio is ranked lower than
94% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SYN: 24.24 )
Ranked among companies with meaningful PB Ratio only.
SYN' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 5.53 Max: 24.76
Current: 24.24
1.61
24.76
EV-to-EBIT -3.03
SYN's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. SYN: -3.03 )
Ranked among companies with meaningful EV-to-EBIT only.
SYN' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.4  Med: -11.4 Max: -1.8
Current: -3.03
-31.4
-1.8
EV-to-EBITDA -3.05
SYN's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. SYN: -3.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.1  Med: -12.2 Max: -1.9
Current: -3.05
-46.1
-1.9
Current Ratio 1.21
SYN's Current Ratio is ranked lower than
85% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SYN: 1.21 )
Ranked among companies with meaningful Current Ratio only.
SYN' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.25 Max: 58.44
Current: 1.21
0.03
58.44
Quick Ratio 1.21
SYN's Quick Ratio is ranked lower than
82% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. SYN: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.41 Max: 58.44
Current: 1.21
0.03
58.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.50
SYN's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SYN: -26.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.4  Med: 0 Max: 0
Current: -26.5
-35.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 46.00
SYN's Price-to-Net-Cash is ranked lower than
90% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. SYN: 46.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SYN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.72  Med: 9.92 Max: 47
Current: 46
0.72
47
Price-to-Net-Current-Asset-Value 30.67
SYN's Price-to-Net-Current-Asset-Value is ranked lower than
87% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. SYN: 30.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SYN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.72  Med: 9.16 Max: 90
Current: 30.67
0.72
90
Price-to-Tangible-Book 23.00
SYN's Price-to-Tangible-Book is ranked lower than
91% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. SYN: 23.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SYN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 8.18 Max: 72
Current: 23
0.55
72
Earnings Yield (Greenblatt) % -33.01
SYN's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. SYN: -33.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SYN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -56.2  Med: -8.8 Max: -3.2
Current: -33.01
-56.2
-3.2

More Statistics

EPS (TTM) $ -0.16
Beta1.51
Short Percentage of Float6.51%
52-Week Range $0.41 - 1.63
Shares Outstanding (Mil)128.46

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.43 -0.60 -0.59
EPS without NRI ($) -0.43 -0.60 -0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}